Comparative Pharmacology
Head-to-head clinical analysis: EXOSURF NEONATAL versus SURVANTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXOSURF NEONATAL versus SURVANTA.
EXOSURF NEONATAL vs SURVANTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Exosurf Neonatal is a synthetic pulmonary surfactant containing dipalmitoylphosphatidylcholine (DPPC), cetyl alcohol, and tyloxapol. It reduces surface tension at the air-liquid interface in the alveoli, preventing alveolar collapse and improving lung compliance and gas exchange.
Survanta is a natural bovine lung extract containing phospholipids, neutral lipids, and surfactant-associated proteins. It reduces surface tension in the alveoli, preventing alveolar collapse at end-expiration and improving lung compliance.
Not applicable; Exosurf Neonatal is an endotracheal surfactant preparation indicated only for neonatal respiratory distress syndrome. No adult dosing exists.
100 mg phospholipids/kg (4 mL/kg) intratracheally, administered as 4 divided aliquots, repeated every 6 hours up to 4 doses as needed.
None Documented
None Documented
Not defined as terminal elimination half-life due to local pulmonary action. Clinical effect persists for 12–24 hours after a single dose, with surfactant pool turnover occurring over days.
terminal elimination half-life of approximately 67 hours (range 37-85 hours) due to slow clearance from lungs; clinically, effects persist for days after single dose
Primarily cleared from lungs via macrophage uptake and catabolism; minimal systemic absorption, thus negligible renal or biliary excretion (<1%). Exogenous surfactant components are recycled and re-secreted by type II pneumocytes.
primarily pulmonary uptake and catabolism; minimal renal or biliary excretion; elimination via alveolar macrophages and recycling in surfactant
Category C
Category C
Pulmonary Surfactant
Pulmonary Surfactant